BOTANIX PHARMACEUTICALS LTD

0.021

0.000

Volume:7.50M

Turnover:153.98K

Market Cap:57.42M

PE:-0.65

High:0.021

Open:0.021

Low:0.020

Close:0.021

52wk High:0.170

52wk Low:0.018

Shares:2.73B

Float Shares:1.72B

Volume Ratio:0.94

T/O Rate:0.44%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.032

EPS(LYR):-0.032

ROE:-96.35%

ROA:-36.86%

PB:0.90

PE(LYR):-0.65

Loading ...

Overview Company News Filings

Botanix Pharmaceuticals Defers API Purchases to 2027, 2028 Under Amended Supply Agreement

MT Newswires Live

·

Mar 30

Botanix Pharmaceuticals' Axillary Hyperhidrosis Product Outsells Competing Product, Says Euroz Hartleys

MT Newswires Live

·

Mar 10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/stock/BOT.AU/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BOT.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"BOT.AU\",,,,,undefined,":{"symbol":"BOT.AU","market":"AU","secType":"STK","nameCN":"BOTANIX PHARMACEUTICALS LTD","latestPrice":0.021,"timestamp":1788156148714,"preClose":0.021,"halted":0,"volume":7498112,"delay":0,"changeRate":0,"nameEN":"BOTANIX PHARMACEUTICALS LTD","floatShares":1717605114,"shares":2734312800,"eps":-0.0322,"marketStatus":"Pre CSPA","change":0,"latestTime":"08-31 16:04:10 AEST","open":0.021,"high":0.021,"low":0.02,"amount":153977,"amplitude":0.047619,"askPrice":0.019,"askSize":8004,"bidPrice":0.023,"bidSize":9,"shortable":3,"etf":0,"ttmEps":-0.0322,"tradingStatus":3,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1788220800000},"marketStatusCode":13,"adr":0,"exchange":"ASX","adjPreClose":0.021,"openAndCloseTimeList":[[1788134400000,1788156000000]],"volumeRatio":0.937484,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"BOT.AU","preClose":0.021,"auctionPrice":0.021,"auctionVolume":100009,"auctionTime":1788156148714,"referencePrice":0.021,"referenceTime":1788156148714,"auction":3,"marketStatus":"盘后竞价","timestamp":1788156148714}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"BOT.AU\",,,,,undefined,":{"symbol":"BOT.AU","floatShares":1717605114,"roa":"-36.86%","roe":"-96.35%","lyrEps":-0.0322,"volumeRatio":0.937484,"shares":2734312800,"dividePrice":0,"high":0.021,"amplitude":0.047619,"preClose":0.021,"low":0.02,"week52Low":0.018,"pbRate":"0.90","psRate":"1.70","week52High":0.17,"institutionHeld":0,"latestPrice":0.021,"committee":-0.997754,"eps":-0.0322,"divideRate":0,"volume":7498112,"delay":0,"ttmEps":-0.0322,"open":0.021,"prevYearClose":0.135,"prevWeekClose":0.021,"prevMonthClose":0.019,"prevQuarterClose":0.019,"fiveDayClose":0.02,"twentyDayClose":0.021,"sixtyDayClose":0.022},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BOT.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BOT.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BOT.AU\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2623536172","title":"Botanix Pharmaceuticals Defers API Purchases to 2027, 2028 Under Amended Supply Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2623536172","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623536172?lang=en_us&edition=fundamental","pubTime":"2026-03-30 09:15","pubTimestamp":1774833312,"startTime":"0","endTime":"0","summary":"Botanix Pharmaceuticals  said it has amended its active pharmaceutical ingredient  supply agreement with Kaken Pharmaceutical, rescheduling purchases to December 2027 and December 2028 from the previously set dates for April 2026 and January 2027, according to a Monday Australian bourse filing.The company said following a recent API purchase earlier this month, no further API purchases are required before December 2027, while activities continue to establish an alternate API supplier for Sofpironium Bromide with a view to de-risking the supply chain and achieving potential savings of 25% to 40% in cost of goods sold.Deferring the purchases, in conjunction with proceeds from the current capital raise if approved, is expected to strengthen Botanix's ability to pursue its plans for Sofdra and its fulfillment platform, the filing added.The company's shares fell 2% in recent Monday trade.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7103","BK7502","BK7508","API","API.AU","OTX.SI","BK4023","BK4503","BK6520","BOT.AU","BK7096","BK4551","BK4535","BK6100"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618398345","title":"Botanix Pharmaceuticals' Axillary Hyperhidrosis Product Outsells Competing Product, Says Euroz Hartleys","url":"https://stock-news.laohu8.com/highlight/detail?id=2618398345","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618398345?lang=en_us&edition=fundamental","pubTime":"2026-03-10 13:11","pubTimestamp":1773119492,"startTime":"0","endTime":"0","summary":"Botanix Pharmaceuticals'  axillary hyperhidrosis product, Sofdra, has exceeded the competing product Qbrexza in the week ending February 27, according to a Tuesday note by Euroz Hartleys.Euroz Hartleys said that an estimated 2,726 prescriptions of Sofdra were dispensed in the period, according to Symphony Health, which shows 15% week-on-week growth and the highest weekly prescription level on record.Given its role as corporate adviser, the research firm said it is restricted from providing a price target or rating at this time.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BOT.AU","BK7096","BK7502","BK7508"],"isVideo":false,"video":null,"gpt_icon":1}],"pageSize":20,"totalPage":2,"pageCount":2,"totalSize":22,"code":"91000000","status":"200"}]}}